BJH - 2023, issue Recent highlights in Acute Leukemia, october 2023
T. Feys MBA, MSc
About half of the adult patients with acute B-cell lymphoblastic leukemia (B-ALL) who do not achieve a molecular complete remission or who subsequently relapse cannot be cured with the current chemotherapy or targeted agents. In recent years, however, we have witnessed the emergence of different immune-based therapies in this setting. This includes monoclonal antibodies, bispecific T-cell engagers (BiTEs), antibodydrug conjugates (ADCs), and chimeric antigen receptor T-cells (CARs).
Read moreBJH - volume 14, issue 5, september 2023
T. Feys MBA, MSc
OVERVIEW OF BELGIAN REIMBURSEMENT NEWS
(BELG J HEMATOL 2023;14(5):230–1)
Read moreBJH - volume 14, issue 4, june 2023
J. Blokken PhD, PharmD, T. Feys MBA, MSc
In this section of the Belgian Journal of Hematology (BJH), we aim to provide a snapshot of pivotal studies published in recent issues of the most important international journals focusing on haematology. Importantly, the selection of the studies discussed here is the sole responsibility of the publisher and was not influenced by third parties. Do you miss an important study, or did you read a hidden jewel that deserves to be shared with your colleagues? Please, let us know (editor@bjh.be) and we will make sure to include it in the journal scan section of the next BJH issue.
(BELG J HEMATOL 2023;14(4):192–5)
Read moreBJH - volume 14, issue 4, june 2023
T. Feys MBA, MSc
OVERVIEW OF BELGIAN REIMBURSEMENT NEWS
(BELG J HEMATOL 2023;14(4):196)
Read moreBJH - volume 14, issue 3, may 2023
J. Blokken PhD, PharmD, T. Feys MBA, MSc
In this section of the Belgian Journal of Hematology (BJH), we aim to provide a snapshot of pivotal studies published in recent issues of the most important international journals focusing on haematology. Importantly, the selection of the studies discussed here is the sole responsibility of the publisher and was not influenced by third parties. Do you miss an important study, or did you read a hidden jewel that deserves to be shared with your colleagues? Please, let us know (editor@bjh.be) and we will make sure to include it in the journal scan section of the next BJH issue.
(BELG J HEMATOL 2023;14(3):145–8)
Read moreBJH - volume 14, issue 3, may 2023
T. Feys MBA, MSc
OVERVIEW OF BELGIAN REIMBURSEMENT NEWS
(BELG J HEMATOL 2023;14(3):149)
Read moreBJH - 2023, issue Special, february 2023
A. Enguita PhD, T. Feys MBA, MSc
Hypereosinophilic syndromes (HES) are a group of disorders characterised by continuously elevated eosinophil count in blood and tissue, associated with eosinophil-mediated organ damage. During the 2023 General Annual Meeting of the Belgian Hematology Society, Prof. Florence Roufosse (Hôpital Erasme, Belgium), walked us through the clinical manifestations of this disease, diagnostic methods and currently available treatments. In this, a special focus was given to the emerging eosinophil-targeted therapies.
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
